Shenzhen Neptunus Interlong Bio-technique Co 8329.HK · HKD
Health Care · HKEX · 🇭🇰 Hong Kong
0.12
+1.69%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Shenzhen Neptunus Interlong Bio-technique Co
Its shares trade on HKEX under the ticker 8329.HK. It has been listed since 12 September 2005. In the fiscal year to 31 December 2025, it reported revenue of CN¥972.0m and a net loss of CN¥40.7m. At that date it held total assets of CN¥1.06bn and shareholders' equity of CN¥647.7m.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. engages in the research and development, production and sales of medicines, the purchase and sales of medicines and healthcare food products. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2005-09-12. The firm operates through three segments. Medicines segment is engaged in the manufacture and sales of medicines. Medicines and Healthcare Products segment is engaged in the sales and distribution of medicines and healthcare products. Research and Development Services of Modern Biological Technology segment is engaged in the provision of research and development services of modern biological technologies, such as in vitro diagnostics reagents businesses. The products of the Company include herbal medicines, generic drugs, transfusion and anti-tumor drugs, among others. The firm mainly operates businesses in China.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 12 Sept 2005
- Employees
- 1,458
- Website
- interlong.com ↗
Leadership
Pay as last reported
- Mr. Feng ZhangExecutive Chairman of the Board, Compliance Officer, since 2011
- Mr. Jian Bo HuangVice General Manager, Joint Company Secretary, Executive Director, since 2008
- Mr. Xiao Guang ZhangExecutive Director, since 2023
- Mr. Man Chao WangExecutive General Manager - Jiangsu Neptunus
- Mr. Hang YuanGeneral Manager - Neptunus Nano, since 2014
- Wai Sum FungJoint Company Secretary
- Ms. Ling Xia MuCompany Secretary
- Mr. Rui JinNon-Executive Director
- Ms. Lin YuNon-Executive Director
- Mr. Yi Fei ZhangNon-Executive Director
- Prof. Ka Yeung PoonIndependent Non-Executive Director
- Mr. Wing Fat YickIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Shenzhen Neptunus Interlong Bio-Technique Co Ltd employs 1,458 full-time employees in Health Care sector.
- The company operates three segments including Medicines, Healthcare Products, and R&D Services.
- Herbal medicines, generic drugs, and transfusion anti-tumor drugs are key products in their portfolio.
Weaknesses
- The company is headquartered in Shenzhen, Guangdong, limiting international expansion.
- Shenzhen Neptunus Interlong Bio-Technique Co Ltd has no international presence beyond China.
- The firm's business is primarily focused on China with no mention of global markets.
Opportunities
- The R&D Services segment offers opportunities in modern biological technologies like in vitro diagnostics reagents.
- The Chinese pharmaceutical market continues to grow with increasing healthcare demand.
- Expanding the Medicines and Healthcare Products segment could capture more domestic market share.
Threats
- The company faces competition from other Chinese pharmaceutical firms in the domestic market.
- Regulatory changes in China's pharmaceutical industry could impact operations.
- Economic downturns in China may reduce healthcare spending and affect sales.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.